Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
Open Access
- 13 May 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 29 (20), 2473-2479
- https://doi.org/10.1093/eurheartj/ehn362
Abstract
In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention. We hypothesized that prasugrel would reduce not only first events but also recurrent primary endpoint events and therefore total events compared with clopidogrel. Poisson regression analysis was performed to compare the number of occurrences of the primary endpoint between prasugrel and clopidogrel in TRITON-TIMI 38. Landmark analytic methods were used to evaluate the risk of a recurrent primary endpoint event following an initial non-fatal endpoint event. Among patients with an initial non-fatal event, second events were significantly reduced with prasugrel compared to clopidogrel (10.8 vs. 15.4%, HR 0.65, 95% CI 0.46–0.92; P = 0.016), as was CV death following the non-fatal event (3.7 vs. 7.1%, HR 0.46, 95% CI 0.25–0.82; P = 0.008). Overall there was a reduction of 195 total primary efficacy events with prasugrel vs. clopidogrel (rate ratio 0.79, 95% CI 0.71–0.87; P < 0.001). Recurrent bleeding events occurred infrequently (TIMI major non-CABG bleeds: four with prasugrel and two with clopidogrel). Study drug discontinuation was frequent following the initial major bleeding event (42% of patients discontinued study drug). While standard statistical analytic techniques for clinical trials censor patients who experience a component of the primary composite endpoint, total cardiovascular events remain important to both patients and clinicians. Prasugrel, a more potent anti-platelet agent, reduced both first and subsequent cardiovascular events compared with clopidogrel in patients with ACS.This publication has 18 references indexed in Scilit:
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesThe New England Journal of Medicine, 2007
- Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent ThrombosisJournal of the American College of Cardiology, 2007
- Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)American Heart Journal, 2006
- Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis: Results of the CREST StudyJournal of the American College of Cardiology, 2005
- Predictors of Hospital Mortality in the Global Registry of Acute Coronary EventsArchives of Internal Medicine, 2003
- Challenges and Opportunities in Quantifying the Quality of Care for Acute Myocardial InfarctionCirculation, 2003
- A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudyThe Lancet, 2001
- TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at PresentationCirculation, 2000
- The TIMI Risk Score for Unstable Angina/Non–ST Elevation MIJAMA, 2000
- Predictors of Outcome in Patients With Acute Coronary Syndromes Without Persistent ST-Segment ElevationCirculation, 2000